Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
The biotech sector has turned hot lately especially after the first full U.S. approval of a COVID-19 vaccine made by Pfizer PFE and BioNTech. This is because the move is likely to spur a new wave of vaccine mandates, thereby resulting in more upside in the sector. Notably, Pfizer’s shot is the first COVID-19 vaccine to receive full regulatory approval in the United States.
The full approval of the vaccine, which had been under an emergency use authorization since December, will help quash the ongoing surge in the COVID-19 Delta variant and push up the vaccination rates. Additionally, the government plans to make COVID-19 vaccine booster shots widely available starting on Sep 20 for adults who completed their initial inoculation in two-dose vaccines made by Moderna Inc MRNA and by Pfizer at least six months ago. The plan so far does not include the Johnson & Johnson's JNJ vaccine, the rollout of which started several months later (read: Biotech ETFs to Benefit From Latest Booster Update).
A separate study from Johnson & Johnson showed that a booster dose of its one-shot coronavirus vaccine generated a big spike in antibodies. It found that a second dose of the JNJ vaccine delivered six months after the first shot resulted in a nine-fold increase in binding antibody levels over those seen 28 days after the first dose. The data comes from two Phase 2 trials conducted in the United States and Europe. Some of the 2,000 or so people in the studies got booster doses six months after their first doses of JNJ's Janssen vaccine.
Additionally, merger and acquisition activities are fueling strength in the sector. In the latest announcement, Pfizer agreed to buy the Canadian drug developer Trillium Therapeutics TRIL for a $2.26 billion, or $18.50 per share, in a cash deal to strengthen its arsenal of blood cancer therapies (read: Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News).
Further, the uptrend in the sector is likely to continue given the impressive industry trends including new drug nods, an accelerated pace of innovation, promising drug launches, the growing importance of biosimilars, cost-cutting efforts, an aging population, expanding insurance coverage, the rising middleclass, insatiable demand for new drugs and ever-increasing spending on healthcare.
Given this, investors could easily tap the bullish trend by considering a near-term long on the biotech sector. Fortunately, with the advent of ETFs, this is quite easy as there are few options to accomplish this task. Below we highlight them and some of the key differences between each
ProShares Ultra Nasdaq Biotechnology BIB
Investors aiming to make big gains in a short span can bet on BIB. It provides twice the daily return of the Nasdaq Biotechnology Index and exchanges 71,000 shares in hand, on average. The fund has an AUM of $286.3 million and charges 95 bps in fees and expenses. It has surged 4.4% in a week.
Direxion Daily S&P Biotech Bull 3x Shares LABU
This fund creates three times leveraged long position on the S&P Biotechnology Select Industry Index. It charges an annual fee of 0.95% and trades in a heavy average daily volume of about 2.8 million shares. The fund has AUM of $837.3 million (read: 5 Best Inverse/Leveraged ETF Areas of Last Week).
While this strategy is highly beneficial for short-term traders, it could lead to huge losses compared to traditional funds in fluctuating or seesawing markets. Further, the funds’ performance could vary significantly from the actual performance of their underlying index over a longer period when compared to the shorter period (such as weeks or months) due to their compounding effect.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Moderna, Inc. (MRNA): Free Stock Analysis Report
ProShares Ultra Nasdaq Biotechnology (BIB): ETF Research Reports
Trillium Therapeutics Inc. (TRIL): Free Stock Analysis Report
Direxion Daily S&P Biotech Bull 3X Shares (LABU): ETF Research Reports
To read this article on Zacks.com click here.